Objectives While previous cost-effectiveness studies on pembrolizumab in stage IV non-
small cell lung cancer (NSCLC) have found these regimens to be cost-effective, their …

Objective To compare the cost-effectiveness of the combination of pembrolizumab and
chemotherapy (Pembro+ Chemo) versus pembrolizumab monotherapy (Pembro) as the first …

Objectives This study aimed to assess the cost-effectiveness of pembrolizumab
monotherapy compared with chemotherapy as first-line treatment in patients with locally …

Objectives Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy
in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from …

Background Anti-PD-1 immunotherapy has dramatically shifted therapeutic perspectives for
advanced non-small cell lung cancer (NSCLC). We assessed cost-effectiveness of anti-PD-1 …

Objective Recently, the significant improvement of atezolizumab and pembrolizumab over
chemotherapy for treatment-naïve stage IV non-small cell lung cancer (NSCLC) has been …

Objective Pembrolizumab+ chemotherapy substantially extends life expectancy for
metastatic non-small cell lung cancer (NSCLC) patients. Its cost-effectiveness (CE) was …

Background Pembrolizumab has shown significant survival benefits in treating
chemotherapy-naïve non-small-cell lung cancer patients (NSCLC) with increased level of …

Objectives Pembrolizumab has shown clinical effectiveness in treating patients with PD-L1
positive metastatic non-small-cell lung cancer (NSCLC) who are chemotherapy-naïve in a …

Background The effectiveness of adding pembrolizumab to chemotherapy improve
outcomes in newly diagnosed metastatic non-small-cell lung cancer (NSCLC). We aimed to …